Fezakinumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | IL-22 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6408H9873N1706O2016S44 |
| Molar mass | 144479.04 g·mol−1 |
  (what is this?) (verify) | |
Research and development
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]
